We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Apply for changes to your marketing authorisation, including minor variations type IA and IB, major variations type II and extensions.
How to package medicines for sale and what information you must provide to consumers and healthcare professionals.
An overview of the process including submitting or fast-tracking an application, naming your medicine and paying fees.
A summary of the types of scientific advice available at the MHRA, the process for getting advice and the fees involved.
Guidance on manufacturing, importing, distributing and supplying specially manufactured or ordered products, including cannabis-based products for medicinal use in humans (CBPMs), known as 'specials'
Pharmacy (P), prescription-only (POM), and general sale list (GSL) medicines: apply to move your medicine to a different classification.
How to register on the MHRA portal and use it to apply for and update marketing authorisations and make other applications.
Guidance for Applicants wishing to apply for a Promising Innovative Medicines designation, pre-submission meeting or an EAMS Scientific Opinion.
Detailed guidance on advertising and promoting medicines.
The process for applicants applying for a paediatric investigation plan (PIP) modification or waiver.
Who can supply and or administer specific medicines to patients without a doctor under a PGD and which medicines can be administered.
How the MHRA processes variations to marketing authorisations.
The Early Access to Medicines Scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions early access to medicines that show early signs of having a major advantage over existing therapeut…
The MHRA will review applications for orphan designation at the time of a marketing authorisation (MA) or variation application.
Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.
How to get a parallel import licence for your medicine in the UK, including pharmacovigilance requirements and submitting your application.
How to get a marketing authorisation (MA) for an advanced therapy medicinal product (ATMP) so it can be sold and/or supplied in the United Kingdom.
Information on comparator products used in studies supporting abridged marketing authorisation application.
How to comply with the requirements on promoting medicines to the public and to prescribers and suppliers of medicines
There are changes to the legislation on reference medicinal products (RMPs) used to support abridged marketing authorisation applications.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).